Tehran University Medical Journal
مجله دانشکده پزشکی، دانشگاه علوم پزشکی تهران
Tehran Univ Med J
Medical Sciences
http://tumj.tums.ac.ir
1
admin
1683-1764
1735-7322
10.18869/acadpub.tumj
000
000
000
fa
jalali
1401
10
1
gregorian
2023
1
1
80
10
online
1
fulltext
other
بررسی عاقبت بیماران مبتلا به لوکمی حاد لنفوسیتی درمانشده با رژیم شیمیدرمانی
Hyper-CVAD: یک گزارش کوتاه
Outcome evaluation of patients with acute lymphocytic leukemia treated by Hyper-CVAD chemotherapy regimen in Omid Hospital, Isfahan, Iran.
مقاله اصیل
Original Article
<span style="font-family:yekanYW;"><span style="font-size:12pt"><span style="line-height:102%"><span style="direction:rtl"><span style="unicode-bidi:embed"><b><i><span lang="FA" style="font-size:10.0pt"><span style="line-height:102%">زمینه و هدف:</span></span></i></b><span lang="FA" style="font-size:10.0pt"><span style="line-height:102%"> رژیم </span></span><span dir="LTR" style="font-size:8.0pt"><span style="line-height:102%">Hyper-CVAD</span></span><span style="font-size:10.0pt"><span style="line-height:102%"> یکی از مهمترین رژیمهای مورد استفاده در درمان بیماران مبتلا به لوکمی حاد لنفوسیتی </span></span><span dir="LTR" style="font-size:8.0pt"><span style="line-height:102%">(ALL)</span></span><span lang="FA" style="font-size:10.0pt"><span style="line-height:102%"> در ایران میباشد.</span></span></span></span></span></span><br>
<span style="font-size:12pt"><span style="line-height:102%"><span style="direction:rtl"><span style="unicode-bidi:embed"><b><i><span lang="FA" style="font-size:10.0pt"><span style="line-height:102%">روش بررسی:</span></span></i></b> <span lang="AR-SA" style="font-size:10.0pt"><span style="line-height:102%">این مطالعه توصیفی در طول بازه زمانی فروردین 1395 تا فروردین 1398، در بیمارستان سیدالشهدا (ع) اصفهان بر روی 90 بیمار مبتلا به </span></span><span dir="LTR" style="font-size:8.0pt"><span style="line-height:102%">ALL</span></span><span lang="AR-SA" style="font-size:10.0pt"><span style="line-height:102%"> تحت درمان با رژیم </span></span><span dir="LTR" style="font-size:8.0pt"><span style="line-height:102%">Hyper-CVAD</span></span><span lang="AR-SA" style="font-size:10.0pt"><span style="line-height:102%"> صورت گرفت. اطلاعات دموگرافیک، بالینی و همچنین اطلاعات مربوط به بقای کلی، بقای بدون پیشرفت بیماری و میزان پاسخدهی کلی بیماران مورد ارزیابی قرار گرفت.</span></span></span></span></span></span><br>
<span style="font-size:12pt"><span style="line-height:102%"><span style="direction:rtl"><span style="unicode-bidi:embed"><b><i><span lang="FA" style="font-size:10.0pt"><span style="line-height:102%">یافتهها:</span></span></i></b> <span lang="AR-SA" style="font-size:10.0pt"><span style="line-height:102%">میانگین بقای کلی و بقای بدون پیشرفت بیماران بهترتیب 93/2</span></span><span lang="AR-SA" style="font-size:8.0pt"><span style="line-height:102%">±</span></span><span lang="AR-SA" style="font-size:10.0pt"><span style="line-height:102%">48/44 ماه و 30/3</span></span><span lang="AR-SA" style="font-size:8.0pt"><span style="line-height:102%">±</span></span><span lang="AR-SA" style="font-size:10.0pt"><span style="line-height:102%">44/44 ماه تخمین زده شد. از بین بیماران، 4/84% وارد بهبودی کامل شدند. متغیر بهبودی کامل به تنهایی بر میزان بقای کلی بیماران موثر میباشد. 40% از بیماران در این مطالعه در نهایت فوت کردهاند.</span></span></span></span></span></span><br>
<span style="font-size:12pt"><span style="line-height:102%"><span style="direction:rtl"><span style="unicode-bidi:embed"><b><i><span lang="FA" style="font-size:10.0pt"><span style="line-height:102%">نتیجهگیری: </span></span></i></b><span lang="AR-SA" style="font-size:10.0pt"><span style="line-height:102%">نتایج بهدست آمده با سایر مطالعات صورت گرفته در این زمینه همخوانی داشت و قابل استفاده جهت مقایسه با رژیم های درمانی جدید است.</span></span></span></span></span></span></span><br>
<div><span style="font-size:12pt"><span style="line-height:120%"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:10.0pt"><span style="line-height:120%">Background:</span></span></i></b><span style="font-size:10.0pt"><span style="line-height:120%"> Since numerous chemotherapy regimens for the treatment of patients suffering from acute lymphoid leukemia (ALL) have been recently developed, having basic information about the previous results of using the Hyper-CVAD regimen in order to compare with other common chemotherapy regimens is essential. The aim of this study was to evaluate demographic, clinical and outcome of ALL patients receiving Hyper-CVAD regimen.</span></span></span></span></span><br>
<span style="font-size:12pt"><span style="line-height:120%"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:10.0pt"><span style="line-height:120%">Methods:</span></span></i></b><span style="font-size:10.0pt"><span style="line-height:120%"> In this retrospective study, nighty eligible ALL patients treated with the Hyper-CVAD chemotherapy regimen in Omid Hospital, Isfahan, Iran during April 2016 till April 2019 were considered. We evaluated the demographic variables, pathological data and other clinical factors by an information sheet designed by main investigator. The main purpose of this study was to evaluate overall survival, progression-free survival, and overall response rate of patients along with patients’ clinical characteristics and other relevant factors using Kaplan-Meier or Cox-regression and other statistical analyses. </span></span></span></span></span></div>
<div>
<table align="center" hspace="0" vspace="0">
<tbody>
<tr>
<td align="left" style="padding-top:0in; padding-right:12px; padding-bottom:0in; padding-left:12px" valign="top">
<div><span style="font-size:12pt"><span style="line-height:120%"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:10.0pt"><span style="line-height:120%">Results:</span></span></i></b><b> </b><span style="font-size:10.0pt"><span style="line-height:120%">The mean overall survival and the median survival of patients were 44.8±2.93 and 36.7±7.47 months; respectively. Also the mean progression free survival of patients was 44.44±3.30 months. More than 84.4% of patients encountered complete remission (CR) after receiving Hyper-CVAD regimen. Reaching to CR had positive significant effects on patients’ overall survival and median survival. However, the bone marrow transplantation variable alone did not affect the patients’ overall survival. The variables such as being B/T Cell ALL, Philadelphia, myeloid marker, and central nervous system involvement did not affect the overall survival of patients but the relapse index indicated the significant effects. The median survival time is higher in patients with no relapse episode. None of the initial lab data had any significant effects on patients’ overall survival.</span></span></span></span></span><br>
<span style="font-size:12pt"><span style="line-height:120%"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:10.0pt"><span style="line-height:120%">Conclusion:</span></span></i></b><span style="font-size:10.0pt"><span style="line-height:120%"> For the first time in Iran, we have obtained the mean survival outcome of ALL patients after applying the Hyper-CVAD regimen. According to the results, the mean overall survival, progression free survival and other survival items in Iranian patients suffering from ALL and receiving Hyper-CVAD regimen were in consistent with previous studies in the world.</span></span><span dir="RTL" lang="AR-SA" style="line-height:120%"><span style="font-family:"B Lotus""></span></span></span></span></span><br>
<span style="font-size:12pt"><span style="line-height:130%"><span new="" roman="" style="font-family:" times=""><span style="font-size:10.0pt"><span style="line-height:130%"></span></span></span></span></span></div>
</td>
</tr>
</tbody>
</table>
</div>
<div></div>
لوکمی حاد لنفوسیتی, رژیم شیمی درمانی, پاسخ کامل, بقا.
acute lymphocytic leukemia, chemotherapy regimen, hyper-cvad, survival.
835
841
http://tumj.tums.ac.ir/browse.php?a_code=A-10-3666-585&slc_lang=other&sid=1
Vahid
Varmazyari
وحید
ورمزیاری